MESO vs DKL Comparison

Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.

Delek Logistics Partners LP owns and operates logistics and marketing assets for crude oil and intermediate and refined products. The company's segment includes Pipelines and Transportation; Pipelines and Transportation and Investments in Pipeline Joint Ventures. It generates maximum revenue from the Pipelines and Transportation segment. The pipelines and Transportation segment consist of pipelines, tanks, offloading facilities, trucks, and ancillary assets, which provide crude oil gathering and crude oil, intermediate and refined products transportation and storage services in support of Delek Holdings' refining operations in Tyler, Texas, El Dorado, Arkansas and Spring, Texas.